Swedish biotech Anocca secured roughly $46 million (SEK 440 million) to support clinical trials of VIDAR-1, its nonviral genome-edited TCR T-cell therapy targeting mutant KRAS in pancreatic cancer. The Phase I multicenter trial is underway in Europe following regulatory authorization. This financing will bolster clinical efforts and pipeline advancement, addressing a critical need for innovative treatments against aggressive pancreatic ductal adenocarcinoma.